<p>Vertex Pharmaceuticals（纳斯达克代码：VRTX - 获取免费报告）在周六发布给客户和投资者的研究报告中，被华尔街 Zen 的股票研究人员将评级从 “买入” 下调至 “持有”。</p>
<p>获取 <strong>Vertex Pharmaceuticals</strong> 的最新消息：</p>
<ul>
<li>CRISPR Therapeutics 在收益后上涨，管道希望增加</li>
</ul>
<p>其他一些分析师也最近对该公司发表了评论。巴克莱将 Vertex Pharmaceuticals 的目标价从 607.00 美元上调至 615.00 美元，并在 5 月 6 日的研究报告中给予该股票 “超配” 评级。Canaccord Genuity Group 将 Vertex Pharmaceuticals 的目标价从 437.00 美元下调至 436.00 美元，并在 5 月 5 日的研究报告中为该公司设定了 “持有” 评级。斯科舍银行将 Vertex Pharmaceuticals 的目标价从 495.00 美元上调至 558.00 美元，并在 2 月 13 日的研究报告中给予该股票 “跑赢大盘” 评级。美国银行将 Vertex Pharmaceuticals 的目标价从 571.00 美元上调至 598.00 美元，并在 3 月 10 日的研究报告中给予该股票 “买入” 评级。最后，Cantor Fitzgerald 重申了 “超配” 评级，并在 2 月 13 日的研究报告中对 Vertex Pharmaceuticals 的股票设定了 590.00 美元的目标价。共有 22 位分析师对该股票给予了买入评级，3 位分析师给予了持有评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “适度买入”，共识目标价为 555.91 美元。</p>
<p><strong>查看我们关于 Vertex Pharmaceuticals 的最新研究报告</strong></p>
<h2>Vertex Pharmaceuticals 股票下跌 0.1%</h2>
<ul>
<li>Royalty Pharma 如何在没有生物技术最大风险的情况下盈利</li>
</ul>
<p>VRTX 的股票在周五开盘价为 447.54 美元。该公司的 50 日简单移动平均线为 439.06 美元，200 日简单移动平均线为 451.64 美元。该股票的市值为 1135.9 亿美元，市盈率为 26.54，PEG 比率为 1.92，贝塔值为 0.30。Vertex Pharmaceuticals 的 52 周低点为 362.50 美元，52 周高点为 507.92 美元。</p>
<p>Vertex Pharmaceuticals（纳斯达克代码：VRTX - 获取免费报告）最近在 5 月 4 日发布了季度财报。该制药公司报告季度每股收益为 4.47 美元，超出分析师一致预期的 4.24 美元，超出幅度为 0.23 美元。该公司在本季度的收入为 29.9 亿美元，而分析师预期的收入为 29.9 亿美元。Vertex Pharmaceuticals 的股本回报率为 23.86%，净利润率为 35.51%。该公司的季度收入同比增长 8.3%。在去年同期，该公司每股收益为 4.06 美元。平均而言，股票分析师预计 Vertex Pharmaceuticals 在当前财年将发布 16.99 美元的每股收益。</p>
<h2>Vertex Pharmaceuticals 的内部活动</h2>
<ul>
<li>2025 年最佳生物技术股票</li>
</ul>
<p>在其他新闻中，董事 Sangeeta N. Bhatia 在 5 月 4 日的交易中出售了 318 股该公司的股票。股票以平均价格 423.73 美元出售，总价值为 134,746.14 美元。出售完成后，该董事直接持有该公司 4,924 股股票，价值 2,086,446.52 美元。此交易代表其持股比例下降了 6.07%。该交易在向证券交易委员会提交的文件中披露，文件可在此链接查看。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，首席营销官 Carmen Bozic 在 5 月 12 日的交易中出售了 6,988 股该公司的股票。股票以平均价格 450.00 美元出售，总价值为 3,144,600.00 美元。出售完成后，首席营销官直接持有该公司 26,088 股股票，价值 11,739,600 美元。该交易使其持股比例下降了 21.13%。该出售的披露信息可在 SEC 文件中找到。该交易是在预先安排的 10b5-1 交易计划下执行的。在过去三个月中，内部人士出售了价值 5,309,945 美元的 11,717 股公司股票。内部人士持有该公司股票的比例为 0.20%。</p>
<h2>机构投资者对 Vertex Pharmaceuticals 的看法</h2>
<p>几家机构投资者最近调整了对该股票的持有。先锋集团在第三季度将其在 Vertex Pharmaceuticals 的股份提高了 1.0%。先锋集团目前持有该制药公司 24,216,865 股股票，价值 9,484,293,000 美元，在上个季度购买了额外的 243,088 股。资本研究全球投资者在第四季度增加了对 Vertex Pharmaceuticals 的持有，增幅为 4.6%。资本研究全球投资者目前持有该制药公司 17,316,344 股股票，价值 7,850,544,000 美元，在此期间购买了额外的 763,063 股。道富银行在第四季度增加了对 Vertex Pharmaceuticals 的持有，增幅为 0.7%。道富银行目前持有该制药公司 11,689,539 股股票，价值 5,299,569,000 美元，在此期间购买了额外的 83,539 股。资本国际投资者在第四季度增加了对 Vertex Pharmaceuticals 的持有，增幅为 0.9%。资本国际投资者目前持有该制药公司 4,733,596 股股票，价值 2,146,041,000 美元，在此期间购买了额外的 44,537 股。最后，Alliancebernstein L.P.在第三季度增加了对 Vertex Pharmaceuticals 的持有，增幅为 3.3%。Alliancebernstein L.P.目前持有该制药公司 4,522,586 股股票，价值 1,771,226,000 美元，在此期间购买了额外的 144,266 股。90.96% 的股票由机构投资者持有。</p>
<h2>关于 Vertex Pharmaceuticals</h2>
<p>（获取免费报告）</p>
<p>Vertex Pharmaceuticals Inc 是一家总部位于波士顿的生物技术公司，专注于严重疾病的治疗方法的发现、开发和商业化。公司成立于 1989 年，凭借以研究为驱动的药物开发建立了声誉，最为人知的是在囊性纤维化（CF）领域的工作，其小分子 CFTR 调节剂的产品组合改变了许多患者的治疗标准。该公司在多个国际市场运营研究与开发、制造和商业组织，为患者和医疗系统提供服务。</p>
<p>Vertex 的市场产品集中在 CFTR 调节剂上，这些药物针对囊性纤维化的根本原因，而不仅仅是治疗症状。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票，胜过 Vertex Pharmaceuticals</li>
<li>股价下跌，目标上升——市场与分析师对 Synopsys 的看法分歧</li>
<li>Salesforce 股票在 AI 势头增强时找到支撑</li>
<li>Dollar Tree 在 Family Dollar 离婚后继续获胜</li>
<li>苹果的代理 AI 计划可能是其最大的增长故事</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Vertex Pharmaceuticals 吗？</h2>
<p>在考虑 Vertex Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Vertex Pharmaceuticals 并不在名单上。</p>
<p>虽然 Vertex Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

福泰制药

标普生物技术 ETF - SPDR

医药突破 ETF - ALPS

<p>华尔街禅将福泰制药（VRTX）的评级从 “买入” 下调至 “持有”。这紧随其后的是近期分析师的行动，包括巴克莱提高了其目标价，加拿大丰业证券设定了 “持有” 评级。该股票最近报告的季度每股收益为 4.47 美元，超出预期，收入为 29.9 亿美元。同时也注意到内部人士的减持，而像先锋集团这样的机构投资者则增加了他们的持股</p>

<p>Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report issued to clients and investors on Saturday.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals（纳斯达克代码：VRTX - 获取免费报告）在周六发布给客户和投资者的研究报告中，被华尔街 Zen 的股票研究人员将评级从 “买入” 下调至 “持有”。</p>
</div><p>Get <strong>Vertex Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Vertex Pharmaceuticals</strong> 的最新消息：</p>
</div><ul>
<li>CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows</li>
</ul>
<div class="lb-trans"><ul>
<li>CRISPR Therapeutics 在收益后上涨，管道希望增加</li>
</ul>
</div><p>A number of other analysts have also recently commented on the company. Barclays upped their price target on Vertex Pharmaceuticals from $607.00 to $615.00 and gave the stock an &#34;overweight&#34; rating in a research report on Wednesday, May 6th. Canaccord Genuity Group reduced their price target on Vertex Pharmaceuticals from $437.00 to $436.00 and set a &#34;hold&#34; rating for the company in a research report on Tuesday, May 5th. Scotiabank upped their price target on Vertex Pharmaceuticals from $495.00 to $558.00 and gave the stock an &#34;outperform&#34; rating in a research report on Friday, February 13th. Bank of America upped their price objective on Vertex Pharmaceuticals from $571.00 to $598.00 and gave the stock a &#34;buy&#34; rating in a research note on Tuesday, March 10th. Finally, Cantor Fitzgerald reaffirmed an &#34;overweight&#34; rating and issued a $590.00 price objective on shares of Vertex Pharmaceuticals in a research note on Friday, February 13th. Twenty-two analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $555.91.</p>
<div class="lb-trans"><p>其他一些分析师也最近对该公司发表了评论。巴克莱将 Vertex Pharmaceuticals 的目标价从 607.00 美元上调至 615.00 美元，并在 5 月 6 日的研究报告中给予该股票 “超配” 评级。Canaccord Genuity Group 将 Vertex Pharmaceuticals 的目标价从 437.00 美元下调至 436.00 美元，并在 5 月 5 日的研究报告中为该公司设定了 “持有” 评级。斯科舍银行将 Vertex Pharmaceuticals 的目标价从 495.00 美元上调至 558.00 美元，并在 2 月 13 日的研究报告中给予该股票 “跑赢大盘” 评级。美国银行将 Vertex Pharmaceuticals 的目标价从 571.00 美元上调至 598.00 美元，并在 3 月 10 日的研究报告中给予该股票 “买入” 评级。最后，Cantor Fitzgerald 重申了 “超配” 评级，并在 2 月 13 日的研究报告中对 Vertex Pharmaceuticals 的股票设定了 590.00 美元的目标价。共有 22 位分析师对该股票给予了买入评级，3 位分析师给予了持有评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “适度买入”，共识目标价为 555.91 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on Vertex Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Vertex Pharmaceuticals 的最新研究报告</strong></p>
</div><h2>Vertex Pharmaceuticals Stock Down 0.1%</h2>
<div class="lb-trans"><h2>Vertex Pharmaceuticals 股票下跌 0.1%</h2>
</div><ul>
<li>How Royalty Pharma Prints Cash Without Biotech's Biggest Risks</li>
</ul>
<div class="lb-trans"><ul>
<li>Royalty Pharma 如何在没有生物技术最大风险的情况下盈利</li>
</ul>
</div><p>Shares of VRTX opened at $447.54 on Friday. The business has a 50-day simple moving average of $439.06 and a two-hundred day simple moving average of $451.64. The stock has a market cap of $113.59 billion, a price-to-earnings ratio of 26.54, a PEG ratio of 1.92 and a beta of 0.30. Vertex Pharmaceuticals has a 52 week low of $362.50 and a 52 week high of $507.92.</p>
<div class="lb-trans"><p>VRTX 的股票在周五开盘价为 447.54 美元。该公司的 50 日简单移动平均线为 439.06 美元，200 日简单移动平均线为 451.64 美元。该股票的市值为 1135.9 亿美元，市盈率为 26.54，PEG 比率为 1.92，贝塔值为 0.30。Vertex Pharmaceuticals 的 52 周低点为 362.50 美元，52 周高点为 507.92 美元。</p>
</div><p>Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last issued its quarterly earnings results on Monday, May 4th. The pharmaceutical company reported $4.47 EPS for the quarter, topping analysts' consensus estimates of $4.24 by $0.23. The business had revenue of $2.99 billion during the quarter, compared to analysts' expectations of $2.99 billion. Vertex Pharmaceuticals had a return on equity of 23.86% and a net margin of 35.51%.The business's quarterly revenue was up 8.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $4.06 earnings per share. On average, equities analysts anticipate that Vertex Pharmaceuticals will post 16.99 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals（纳斯达克代码：VRTX - 获取免费报告）最近在 5 月 4 日发布了季度财报。该制药公司报告季度每股收益为 4.47 美元，超出分析师一致预期的 4.24 美元，超出幅度为 0.23 美元。该公司在本季度的收入为 29.9 亿美元，而分析师预期的收入为 29.9 亿美元。Vertex Pharmaceuticals 的股本回报率为 23.86%，净利润率为 35.51%。该公司的季度收入同比增长 8.3%。在去年同期，该公司每股收益为 4.06 美元。平均而言，股票分析师预计 Vertex Pharmaceuticals 在当前财年将发布 16.99 美元的每股收益。</p>
</div><h2>Insider Activity at Vertex Pharmaceuticals</h2>
<div class="lb-trans"><h2>Vertex Pharmaceuticals 的内部活动</h2>
</div><ul>
<li>Best Biotech Stocks to Buy in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2025 年最佳生物技术股票</li>
</ul>
</div><p>In other news, Director Sangeeta N. Bhatia sold 318 shares of the firm's stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $423.73, for a total value of $134,746.14. Following the completion of the sale, the director directly owned 4,924 shares of the company's stock, valued at $2,086,446.52. This trade represents a 6.07% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Carmen Bozic sold 6,988 shares of the firm's stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $450.00, for a total value of $3,144,600.00. Following the completion of the sale, the chief marketing officer directly owned 26,088 shares of the company's stock, valued at $11,739,600. The trade was a 21.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 11,717 shares of company stock valued at $5,309,945. Insiders own 0.20% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，董事 Sangeeta N. Bhatia 在 5 月 4 日的交易中出售了 318 股该公司的股票。股票以平均价格 423.73 美元出售，总价值为 134,746.14 美元。出售完成后，该董事直接持有该公司 4,924 股股票，价值 2,086,446.52 美元。此交易代表其持股比例下降了 6.07%。该交易在向证券交易委员会提交的文件中披露，文件可在此链接查看。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，首席营销官 Carmen Bozic 在 5 月 12 日的交易中出售了 6,988 股该公司的股票。股票以平均价格 450.00 美元出售，总价值为 3,144,600.00 美元。出售完成后，首席营销官直接持有该公司 26,088 股股票，价值 11,739,600 美元。该交易使其持股比例下降了 21.13%。该出售的披露信息可在 SEC 文件中找到。该交易是在预先安排的 10b5-1 交易计划下执行的。在过去三个月中，内部人士出售了价值 5,309,945 美元的 11,717 股公司股票。内部人士持有该公司股票的比例为 0.20%。</p>
</div><h2>Institutional Investors Weigh In On Vertex Pharmaceuticals</h2>
<div class="lb-trans"><h2>机构投资者对 Vertex Pharmaceuticals 的看法</h2>
</div><p>Several institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its stake in shares of Vertex Pharmaceuticals by 1.0% in the 3rd quarter. Vanguard Group Inc. now owns 24,216,865 shares of the pharmaceutical company's stock valued at $9,484,293,000 after purchasing an additional 243,088 shares during the last quarter. Capital Research Global Investors increased its holdings in Vertex Pharmaceuticals by 4.6% during the 4th quarter. Capital Research Global Investors now owns 17,316,344 shares of the pharmaceutical company's stock worth $7,850,544,000 after purchasing an additional 763,063 shares during the period. State Street Corp increased its holdings in Vertex Pharmaceuticals by 0.7% during the 4th quarter. State Street Corp now owns 11,689,539 shares of the pharmaceutical company's stock worth $5,299,569,000 after purchasing an additional 83,539 shares during the period. Capital International Investors increased its holdings in Vertex Pharmaceuticals by 0.9% during the 4th quarter. Capital International Investors now owns 4,733,596 shares of the pharmaceutical company's stock worth $2,146,041,000 after purchasing an additional 44,537 shares during the period. Finally, Alliancebernstein L.P. increased its holdings in Vertex Pharmaceuticals by 3.3% during the 3rd quarter. Alliancebernstein L.P. now owns 4,522,586 shares of the pharmaceutical company's stock worth $1,771,226,000 after purchasing an additional 144,266 shares during the period. 90.96% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>几家机构投资者最近调整了对该股票的持有。先锋集团在第三季度将其在 Vertex Pharmaceuticals 的股份提高了 1.0%。先锋集团目前持有该制药公司 24,216,865 股股票，价值 9,484,293,000 美元，在上个季度购买了额外的 243,088 股。资本研究全球投资者在第四季度增加了对 Vertex Pharmaceuticals 的持有，增幅为 4.6%。资本研究全球投资者目前持有该制药公司 17,316,344 股股票，价值 7,850,544,000 美元，在此期间购买了额外的 763,063 股。道富银行在第四季度增加了对 Vertex Pharmaceuticals 的持有，增幅为 0.7%。道富银行目前持有该制药公司 11,689,539 股股票，价值 5,299,569,000 美元，在此期间购买了额外的 83,539 股。资本国际投资者在第四季度增加了对 Vertex Pharmaceuticals 的持有，增幅为 0.9%。资本国际投资者目前持有该制药公司 4,733,596 股股票，价值 2,146,041,000 美元，在此期间购买了额外的 44,537 股。最后，Alliancebernstein L.P.在第三季度增加了对 Vertex Pharmaceuticals 的持有，增幅为 3.3%。Alliancebernstein L.P.目前持有该制药公司 4,522,586 股股票，价值 1,771,226,000 美元，在此期间购买了额外的 144,266 股。90.96% 的股票由机构投资者持有。</p>
</div><h2>About Vertex Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Vertex Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals Inc 是一家总部位于波士顿的生物技术公司，专注于严重疾病的治疗方法的发现、开发和商业化。公司成立于 1989 年，凭借以研究为驱动的药物开发建立了声誉，最为人知的是在囊性纤维化（CF）领域的工作，其小分子 CFTR 调节剂的产品组合改变了许多患者的治疗标准。该公司在多个国际市场运营研究与开发、制造和商业组织，为患者和医疗系统提供服务。</p>
</div><p>Vertex's marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.</p>
<div class="lb-trans"><p>Vertex 的市场产品集中在 CFTR 调节剂上，这些药物针对囊性纤维化的根本原因，而不仅仅是治疗症状。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Vertex Pharmaceuticals</li>
<li>Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys</li>
<li>Salesforce Stock Finds Support as AI Momentum Builds</li>
<li>Dollar Tree Keeps Winning After Family Dollar Divorce</li>
<li>Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Vertex Pharmaceuticals</li>
<li>股价下跌，目标上升——市场与分析师对 Synopsys 的看法分歧</li>
<li>Salesforce 股票在 AI 势头增强时找到支撑</li>
<li>Dollar Tree 在 Family Dollar 离婚后继续获胜</li>
<li>苹果的代理 AI 计划可能是其最大的增长故事</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=VRTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Vertex Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Vertex Pharmaceuticals 吗？</h2>
</div><p>Before you consider Vertex Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Vertex Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Vertex Pharmaceuticals 并不在名单上。</p>
</div><p>While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Vertex Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Wall Street Zen Downgrades Vertex Pharmaceuticals (NASDAQ:VRTX) to Hold

Market Beat

标普生物技术 3 倍做空 - Direxion

标普全球医疗股指数 ETF - iShares

医疗业 ETF - SPDR

2 倍做空纳斯达克生物技术 ETF - ProShares

纳斯达克生物科技指数 ETF - iShares Nasdaq

纽交所高增长板生物技术指数 ETF - First Trust

2 倍做多纳斯达克生物技术 ETF - ProShares

医疗业 ETF - Vanguard

美国制药 ETF - iShares

生物科技 ETF - VanEck Vectors

动态生物技术与基因组 ETF - Invesco

标普生物技术 3 倍做多 - Direxion

基因改革 ETF - ARK

CRISPR治疗

巴克莱银行

美国银行

Royalty Pharma PLC - CL

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

华尔街禅将福泰制药（纳斯达克代码：VRTX）的评级下调至持有